← FDA DRUG APPROVALS

FDA ANDA · ANDA202590

LEVOFLOXACIN

Sponsor: AVET LIFESCIENCES

APPLICATION
ANDA202590
TYPE
ANDA
ORIGINAL APPROVAL
2013-01-24
LATEST ACTION
2024-09-20
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

LEVOFLOXACINDiscontinued
LEVOFLOXACIN EQ 500MG/20ML (EQ 25MG/ML) · INJECTABLE · INJECTION
LEVOFLOXACINDiscontinued
LEVOFLOXACIN EQ 750MG/30ML (EQ 25MG/ML) · INJECTABLE · INJECTION

Approval history

2024-09-20Labeling · Supplement 12 · standardAP
2024-01-11Labeling · Supplement 11 · standardAP
2019-05-03Labeling · Supplement 10 · standardAP
2019-04-17Labeling · Supplement 6 · standardAP
2018-10-18Labeling · Supplement 9 · standardAP
2016-07-14Labeling · Supplement 1 · standardAP
2016-07-14Labeling · Supplement 2 · standardAP
2013-01-24UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →